Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist

Due to the absence of curative treatments for glioblastoma (GBM), we assessed the efficacy of single and combination treatments with a translationally relevant 2nd generation TRAIL-receptor agonist (IZI1551) and the blood–brain barrier (BBB) permeant proteasome inhibitor marizomib in a panel of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccellato, Chiara, Kolbe, Emily, Peters, Nathalie, Juric, Viktorija, Fullstone, Gavin, Verreault, Maïté, Idbaih, Ahmed, Lamfers, Martine L. M., Murphy, Brona M., Rehm, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225658/
https://www.ncbi.nlm.nih.gov/pubmed/34168123
http://dx.doi.org/10.1038/s41419-021-03927-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225658/
https://www.ncbi.nlm.nih.gov/pubmed/34168123
http://dx.doi.org/10.1038/s41419-021-03927-x

Ejemplares similares